Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation

Abstract

Introduction: Alzheimer's disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data from the large phase III CLARITY AD trial were used to estimate the societal value of lecanemab plus standard of care (SoC) versus SoC alone against a range of willingness-to-pay (WTP) thresholds from a healthcare and societal perspective in Japan. Methods: A disease simulation model was used to evaluate the impact of lecanemab on disease

Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome

“…These included the federal Advisory Council on Alzheimer's Research, Care, and Supports, which is responsible for developing the National Plan to Address Alzheimer's Disease, 38 Additionally, the process undertaken by the Working Group to address language and criteria modifications in the United States may offer valuable insights for other countries as jurisdictions approve anti-amyloid mAbs use. 40,41,42,43 Since drug approval and prescribing criteria decisions often occur at the national level, the Working Group's experience can serve as a model for advocating for equity in access within other countries, 44 especially through advocacy by intellectual disability or DS advocacy organizations. 45 Its recommendations and insights can also serve as a valuable resource for policymakers, healthcare providers, and advocates working toward improving the quality of care and life for this at-risk population.…”